The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada - 1997 results from the SENTRY Antimicrobial Surveillance Program

Diagnostic Microbiology and Infectious Disease

Volumn 32, Issue 4, 1998, Pages 313-316

  Doern, Gary V ^a   Pfaller, Michael A ^a   Erwin, Meridith E ^a   Brueggemann, Angela B ^a   Jones, Ronald N ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CANADA; CONTROLLED STUDY; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

ANTI-INFECTIVE AGENTS; CANADA; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; PREVALENCE; RESPIRATORY TRACT INFECTIONS; STREPTOCOCCUS PNEUMONIAE; UNITED STATES;

EID: 0032436039     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(98)00081-9     Document Type: Article

References (15)

1. Ballow CH, Jones RN, Johnson DM, Deinhart JA, Schentag JJ, the SPAR Study Group (1997) Comparative in vitro assessment of sparfloxacin activity and spectrum using results from over 14,000 pathogens isolated at 190 medical centers in the USA. Diagn Microbiol Infect Dis 29: 173-186.
2. Brueggemann AB, Kugler KC, Doern GV (1997) In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother 41: 594-1597.
3. Craig WA (1997) Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1-12.
4. Doern GV, Pfaller MA, Kugler K, Freeman J, Jones RN (1998) Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY Antimicrobial Surveillance Program. Clin Infect Dis (Accepted for publication)
5. Eliopoulos GM, Klimm K, Eliopoulos CT, Ferraro MJ, Moellering Jr RC (1993) In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of Gram-positive bacteria. Antimicrob Agents Chemother 37:366-370.
6. Gootz TD, Zaniewski R, Haskell S, Schmieder B, Tankovic J, Girard D, Courvalin P, Polzer RJ (1996) Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyprase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro. Antimicrob Agents Chemother 40:2691-2697.
7. Jones RN, Hoban DJ, The North American Ofloxacin Study Group (1994) North American (United States and Canada) comparative susceptibility of two fluoroquinolones: Ofloxacin and ciprofloxacin. A 53-medical center sample of spectra of activity. Diagn Microbiol Infect Dis 18:49-56.
8. Jones RN, Ballow CH, Schentag JJ, Johnson DM, Deinhart JA, the SPAR Study Group (1998a) In vitro evaluation of sparfloxacin activity and spectrum Against 24,940 pathogens isolated in the United States and Canada, the final analysis. Diagn Microbiol Infect Dis 30:1-21.
9. Jones RN, Johnson DM, Erwin ME, Beach ML, Biedenbach DJ, Pfaller MA, the Quality Control Study Group (1998b) Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and Etest method validation. Diagn Microbiol Infect Dis (accepted for publication).
10. National Committee for Clinical Laboratory Standards (1997) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, PA.
11. Pan X-S, Ambler J, Mehtar S, Fisher LM (1996) Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother 40:2321-2326.
12. Perez-Trallero E, Garcia-Arenzana JM, Jimenez JA, Peris A (1990) Therapeutic failure and selection of resistance to quinolones in a case of pneumococcal pneumonia treated with ciprofloxacin. Eur J Clin Microbiol Infect Dis 9:905-906.
13. Plouffe JF, the Franklin County Pneumonia Study Group (1996) Levofloxacin in vitro activity against bacteremic isolates of S. pneumoniae. Diagn Microbiol Infect Dis 25: 43-45.
14. Trautmann M, Ruhnke M, Borner K, Wagner J, Koeppe P (1996) Pharmacokinetics of sparfloxacin and serum bactericidal activity against pneumococci. Antimicrob Agents Chemother 40:776-779.
15. Wakebe H, Imada T, Yoneda H, Mukai F, Ohguro K, Ohmori K, Tamaoka H, Yabuuchi Y (1994) Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections. Antimicrob Agents Chemother 38:2340-2345.